Structural highlights
6hju is a 1 chain structure with sequence from Equus caballus. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
|
| Ligands: | , , , , , |
| Resources: | FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT |
Function
[FRIL_HORSE] Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity).
Publication Abstract from PubMed
AIM: A Pt(II)-terpyridine compound, bearing two piperidine substituents at positions 2 and 2' of the terpyridine ligand (1), is highly cytotoxic and shows a mechanism of action distinct from cisplatin. 1 has been incorporated within the ferritin nanocage (AFt). MATERIALS & METHODS: Spectroscopic and crystallographic data of the Pt(II)-AFt nanocomposite have been collected and in vitro anticancer activity has been explored using cancer cells. RESULTS: Pt(II)-containing fragments bind His49, His114 and His132. Pt(II)-AFt nanocomposite is less cytotoxic than 1, but it is more toxic than cisplatin at high concentrations. The Pt(II)-AFt nanocomposite triggers necrosis in cancer cells, as free 1 does. CONCLUSION: Pt(II)-AFt nanocomposites are promising vehicles to deliver Pt-based drugs to cancer cells.
Preparation, structure, cytotoxicity and mechanism of action of ferritin-Pt(II) terpyridine compound nanocomposites.,Ferraro G, Pica A, Petruk G, Pane F, Amoresano A, Cilibrizzi A, Vilar R, Monti DM, Merlino A Nanomedicine (Lond). 2018 Dec 3. doi: 10.2217/nnm-2018-0259. PMID:30501559[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Ferraro G, Pica A, Petruk G, Pane F, Amoresano A, Cilibrizzi A, Vilar R, Monti DM, Merlino A. Preparation, structure, cytotoxicity and mechanism of action of ferritin-Pt(II) terpyridine compound nanocomposites. Nanomedicine (Lond). 2018 Dec 3. doi: 10.2217/nnm-2018-0259. PMID:30501559 doi:http://dx.doi.org/10.2217/nnm-2018-0259
